According to a publication from BusinessWire, the Maryland-based pharmaceutical company OncoImmune, Inc. has announced successful phase 2 trial results for its acute graft versus host disease (GVHD) drug CD24Fc. Graft…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
